Tobacco Update: Scientific Advances, Clinical PerspectivesSerious Mental Illness and Tobacco Addiction: A Model Program to Address This Common but Neglected Issue
Section snippets
The Impact of Smoking
The primary concern with tobacco use is that it causes considerable morbidity and mortality in all smokers.6., 7., 8. The rates of cancer and cardiovascular and respiratory diseases among persons with SMI are double those of age-matched control subjects because of the 2- to 3-fold increased rate of tobacco addiction.9., 10. In addition to increased medical comorbidity, smokers with SMI experience increased psychiatric symptoms, hospitalizations, and need for higher medication doses compared
Effects on Medications
The liver cytochrome P450 enzymes metabolize tobacco as well as many psychiatric medications, including commonly used antipsychotic, antianxiety, and antidepressant medications.12 Tobacco (not nicotine) induces the CYP1A2 isoenzyme, resulting in increased metabolism and thus an increased clearance rate of these medications. Smokers often require about double the medication dosage (for CYP1A2-metabolized medications) compared with nonsmokers, often leading to increased side effects and costs.
Factors Increasing Tobacco Dependence among Persons with SMI
There is no simple explanation for the prevalence of smoking among persons with SMI. It is most likely that biological, psychological, and social risk factors contribute to the phenomenon, including neurobiological vulnerability, increased severity of withdrawal symptoms, poor coping skills, and self-medication for attention, mood, and anxiety symptoms. Furthermore, the social reinforcements to smoke in mental health and addiction treatment settings are contributory.14., 15.
As with other
Tobacco Control and Mental Health System Changes
To improve the manner in which we address tobacco use, one option is to use the co-occurring mental illness and addiction paradigm. Available evidence supports the use of an integrated treatment to produce the best outcomes. Within the existing mental health team approach, we developed a model in which psychiatric and nicotine dependence treatment medications are prescribed by the team psychiatrist (or advance practice nurse), addressing tobacco becomes part of the agenda in current mental
Program Development and Consultation
The UMDNJ Tobacco Dependence Program, under the leadership of Drs. Ziedonis, Foulds, and Williams, has developed an effective model for treating tobacco in persons with SMI and a model for instituting changes to better address tobacco in other mental health settings. Dr. John Slade had originally founded this program to address tobacco in addiction treatment settings, and the model has been adapted for the special issues within mental health settings. The UMDNJ Program is described on its web
The UMDNJ Nicotine Craving Laboratory
The cue exposure paradigm offers a unique method to systematically prime patients with drug cues40 and to test out the efficacy of anticraving medications.41 At the Veterans Administration New Jersey Health Care System and Robert Wood Johnson Medical School, we have developed a cocaine craving laboratory and are now expanding this initiative into a nicotine craving laboratory. A large body of research has accumulated over the years to suggest that cue exposure is a reliable method for studying
A National Plan to Address Tobacco in Mental Health Settings
There is a great need for a national strategic plan to address tobacco dependence among persons with SMI. The SAMHSA Report to Congress on Co-occurring Addiction and Mental Illness49 includes tobacco and mental illness as a subtype of co-occurring disorder. During the same period (November 2002 through June 2003), a series of meetings on addressing tobacco among persons with mental illness and addictions occurred that, for the first time, brought together researchers, clinicians,
References (50)
- et al.
Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers
Biol Psychiatry
(1997) - et al.
Smoking and therapeutic response to clozapine in patients with schizophrenia
Biol Psychiatry
(1999) - et al.
A neurobiological basis for substance abuse comorbidity in schizophrenia
Biol Psychiatry
(2001) - et al.
Smoking, smoking withdrawal, and schizophrenia: case reports and a review of the literature
Schizophr Res
(1996) - et al.
Smoking habits and attitudes in a methadone maintenance treatment population
Drug Alcohol Depend
(1997) - et al.
A placebo controlled trial of bupropion for smoking cessation in schizophrenia
Biol Psychiatry
(2002) - et al.
Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride
Addict Behav
(1992) - et al.
Smoking and mental illness: a population-based prevalence study
JAMA
(2000) The relationship between tobacco use and mental disorders
Curr Opin Psychiatry
(1999)- et al.
Nicotine dependence and schizophrenia
Hosp Community Psychiatry
(1994)
Addressing tobacco through program and system change in mental health and addiction settings
Psychiatr Ann
Mortality following inpatient addictions treatment
JAMA
Causes of the excess mortality of schizophrenia
Br J Psychiatry
The association of medical comorbidity in schizophrenia with poor physical and mental health
J Nerv Ment Dis
Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings
Am J Psychiatry
Management of medical illness in persons with schizophrenia
Psychiatr Ann
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects
Am J Psychiatry
Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective
CNS Drugs
Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine
Int Clin Psychopharmacol
Schizophrenia and nicotine use: report of a pilot smoking cessation program and of neurobiological and clinical issues
Schizophr Bull
Pharmacotherapy treatments for tobacco dependence among smokers with mental illness or addiction
Psychiatr Ann
Normalization of auditory physiology by cigarette smoking in schizophrenic patients
Am J Psychiatry
Effects of clozapine on smoking in chronic schizophrenic outpatients
J Clin Psychiatry
Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol
Neuropsychobiology
Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia
Am J Psychiatry
Cited by (108)
Undergraduate psychiatry in India: A SWOT analysis
2018, Asian Journal of PsychiatryPilot study of a video intervention to reduce anxiety and promote preparedness for lung cancer screening
2018, Cancer Treatment and Research CommunicationsCitation Excerpt :By nature of these risk factors, the current screening population is likely to have co-morbidities, such as pulmonary and cardiovascular illnesses, that may already influence their HRQOL. [18] Screen-related anxiety is especially important among smokers, a population with higher rates of mental illness compared with non-smokers. [19] In the NELSON trial, current smokers reported higher levels of anxiety and lower HRQOL. [20–22]
Smoking cessation behaviors among persons with psychiatric diagnoses: Results from a population-level state survey
2014, Drug and Alcohol DependenceComorbid Addictions and Schizophrenia
2013, Interventions for Addiction: Comprehensive Addictive Behaviors and Disorders
This work was supported in part by Center for Substance Abuse Treatment grant DK1-TI12549-01 (to dmz), National Institute on Drug Abuse grants R01-DA15978-01 and R01-DA015537 (to dmz) and K-DA14009-01 (to jmw). dmz and jmw are also supported in part by the New Jersey Department of Health and Senior Services through the Comprehensive Tobacco Control Program and the Robert Wood Johnson Foundation.